SCIENTIFIC HUB

Follow the evidence.

107.521 articles found

Source record

A Phase 2b, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of intravenous prasinezumab in early-stage Parkinson's disease (PADOVA): Rationale, design, and baseline data.

Nikolcheva T, Pagano G, Pross N, Simuni T, Marek K, Postuma RB, Pavese N, Stocchi F, Seppi K, Monnet A, Shariati N, Ricci B, Rutten-Jacobs L, Respondek G, Kustermann T, Taylor KI, Trundell D, Fontoura P, Doody R, Svoboda H, Bonni A, PADOVA Investigators and Prasinezumab Study Group.

Parkinsonism Relat Disord · 2024-12-29

DOI: 10.1016/j.parkreldis.2024.107257PMID: 39798255

A bibliographic record traceable to Europe PMC. Türkçe başlık: makine çevirisi, editoryal kontrol bekliyor.
Source record

Expanded and independent validation of the NoMoFA scale for Parkinson's disease: the Italian version.

Balestrino R, Rinaldi D, Galli S, Romagnolo A, Erro R, Ledda C, Donzuso G, Picillo M, Terravecchia C, Agosta F, Barone P, Lopiano L, Nicoletti A, Filippi M, Martinez-Martin P, Artusi CA.

J Neurol · 2024-12-28

DOI: 10.1007/s00415-024-12863-7PMID: 39733007

A bibliographic record traceable to Europe PMC. Türkçe başlık: makine çevirisi, editoryal kontrol bekliyor.

Records come from scientific sources. Bibliographic counts do not represent completed translations or editorial approvals.

Filters

Filters

Clear
Publication year
Research area
Author
Journal
Publication type
Source & language
Open accessAccess does not establish reuse rights.